R. Bergamaschi, M. Capobianco, and R. Ravasio, “Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy”, AboutOpen, vol. 11, no. 1, pp. 48–56, Jun. 2024.